Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer

Inclusion Criteria:

• Age ≥18 years old
• Patients must have histologically confirmed cervical cancer with adenocarcinoma,adenosquamous or squamous histology and FIGO 2018 Ib3-IIIc2.
• According to the RECIST 1.1 standard, the subject must have at least one measurabletarget lesion
• No prior treatment
• Expected survival period ≥ 3 months
• ECOG score: 0-1
• No obvious signs of hematological diseases, ANC≥1.5×10^9/L, platelet count≥100×10^9/L,Hb≥90g/L, WBC≥3.0×10^9/L, and no bleeding tendency before enrollment;
• Adequate hepato-renal function is needed, including: Total bilirubin (TBIL)≤1.5×ULN (Gilbert syndrome allows ≤5×ULN) Alanine aminotransferase (ALT) and aspartateaminotransferase (AST) ≤2.5×ULN Serum creatinine (Cr) ≤ 1.5 × ULN or endogenouscreatinine clearance ≥ 50mL/min
• Cardiac Function: left ventricular ejection fraction (LVEF) >=50%;
• Patients voluntarily participated in the study and signed informed consent

Exclusion Criteria:

• Pregnant or breastfeeding female patients (women of child-bearing potential mustconfirm that the pregnancy test is negative within 7 days before the firstadministration. If it is positive, ultrasound examination must be performed to excludepregnancy), or women of child-bearing potential who refused to receive contraceptivemeasures
• Combined with other malignant tumors, except for cured skin basal cell carcinoma orskin squamous cell carcinoma or carcinoma in situ of any other part
• Existence of any bone marrow dysplasia and other abnormal hematopoietic diseases
• Active infections, HIV infections, and viral hepatitis that require systematictreatment
• Patients with≥Grade 1 peripheral neuropathy according to the National Cancer InstituteCommon Toxicity Criteria (NCI-CTC) Version 5.0
• Had severe cardiovascular diseases such as cerebrovascular accident, myocardialinfarction, hypertension that cannot be controlled after drug intervention, unstableangina pectoris, heart failure (NYHA 2-4) and arrhythmia that need drug interventionwithin 6 months
• It is known to have a history of allergies to research drugs or drug components
• Has clinically significant thyroid dysfunction before enrollment;
• Has participated in other anti-tumor intervention clinical trials within 30 daysbefore the first medication
• Have a clear history of dementia, mental state changes or any mental illness that willhinder understanding or informed consent
• The investigator believes that the patient is not suitable for participating in thisclinical research